+1 915 229 3004 (U.S.) | 
+44 7452 242832 (U.K.)
+1 915 229 3004 (U.S.) | +44 7452 242832 (U.K.)
In 2022, the global market for therapeutics addressing autism spectrum disorder (ASD) reached a valuation of USD 1.94 billion. The market is anticipated to demonstrate consistent growth, projected to increase from USD 2.05 billion in 2023 to USD 3.43 billion by 2030, with a Compound Annual Growth Rate (CAGR) of 7.90% during the forecast period.
Download Free Sample to learn more about this report
Autism spectrum disorder, encompassing conditions like autistic disorder, Asperger's syndrome, and Pervasive Developmental Disorder (PDD), is characterized by persistent deficits in social interaction and communication, along with repetitive or restricted patterns of behavior. The prevalence of ASD globally, affecting millions, has been highlighted in a 2020 report by the Centers for Disease Control & Prevention (CDC), indicating that 1 in 54 children in the U.S. has been diagnosed with autism disorder.
Factors contributing to the market's growth include the increasing global prevalence of ASD, heightened awareness, and available treatment options. Key players' investments in research and development (R&D) for effective drugs to treat autistic disorders further contribute to the market's expansion.
The COVID-19 pandemic initially disrupted healthcare processes and therapy services, leading to a slowdown in manufacturing and therapy sessions' postponement. However, the adoption of telehealth systems by caregivers and families, driven by the vulnerable nature of autistic patients to the virus, contributed to robust demand for drugs. Notably, drugs such as Abilify Maintena recorded increased sales trends. Despite initial challenges, the pandemic had a positive impact on market growth, with steady growth observed in 2022 due to the resumption of R&D activities and expected launches of pipeline candidates.
Enzyme Replacement Therapy (ERT) has emerged as a novel approach for ASD treatment. ASD, being a lifelong disorder with diverse challenges for patients and caregivers, often presents additional medical conditions like gastrointestinal distress. Enzyme replacement therapy, addressing the difficulty in digesting certain proteins associated with autism, has gained prominence. For example, Curemark's CM-AT, an FDA-designated "Fast Track" drug for children with autism, focuses on the enzyme chymotrypsin essential for breaking down dietary proteins.
The rising prevalence of ASD globally is a major driver propelling market growth. The demand for clinical research aimed at effective treatment options has increased, contributing to improved patient outcomes and diagnostic accuracy. Notably, regions like the Middle East exhibit higher prevalence rates, creating a demand for effective drugs.
Government initiatives globally, such as funding for autism awareness and support programs, play a significant role in boosting market growth. Initiatives like those undertaken by the Saskatchewan Government in Canada contribute to early diagnosis, symptom awareness, and increased demand for autism treatment drugs.
Despite the increasing demand for effective drugs and clinical trials, there is currently no cure for ASD, hampering market growth. Challenges in drug development, including weaknesses in methods, knowledge gaps, and conceptual models in clinical translation research, pose obstacles. Ongoing efforts to develop various molecules have not provided conclusive evidence supporting any drug's efficacy for core symptom treatment.
The market is segmented based on drug therapy, disease, age group, distribution channel, and geography.
Stimulants emerge as the dominant segment due to their role in decreasing hyperactivity in people with autism.
Antipsychotic drugs, SSRIs/antidepressants, sleep medications, and others contribute to the diverse drug therapy landscape.
Autistic disorder holds a dominant market share in 2022, driven by its high prevalence.
Asperger syndrome, pervasive developmental disorder (PDD), and others contribute to the segmentation.
The children segment is expected to grow at a faster pace due to an increase in early-age diagnoses.
The adult segment holds a significant market share, fueled by the growing number of service providers offering therapies.
Hospital pharmacies dominate the market, as most therapeutics require professional examinations.
Drug stores & retail pharmacies and online pharmacies also contribute to market share.
The North America market size was USD 1.12 billion in 2022, attributed to the increasing prevalence of autism disorder and strong government support.
The U.S. witnessed tripled autism prevalence since 2000, contributing to the region's dominance.
Europe is the second-largest region, benefiting from increased awareness, screening, and product sales.
Government support and broadened diagnostic criteria contribute to the region's growth.
Asia Pacific is projected to grow with the highest CAGR due to rising demand for effective treatment and healthcare infrastructure development.
These regions show a slower growth rate due to lower reported autism rates and a lack of product approvals.
Continuous R&D initiatives and strategic acquisitions by key players are anticipated to surge sales growth. Key players include Otsuka Holdings Co. Ltd., H. Lundbeck A/S, Janssen Pharmaceuticals, Inc., and Sanofi. Others such as Alembic Pharmaceuticals Limited, Teva Pharmaceutical Industries Ltd., and Aurobindo Pharma specialize in manufacturing generic versions of drugs for ASD treatment.
· F. Hoffmann-La Roche Ltd's drug candidate RO7017773 is in an ongoing phase 2 trial for ASD treatment, with a regulatory filing planned for 2024.
· Yamo Pharmaceuticals received investment from The Autism Impact Fund to support Phase 2 candidate study of L1-79 in adolescents and adults with ASD.
· Axial Therapeutics received FDA clearance for its lead candidate AB-2004, a gut-targeted molecular therapeutic for ASD-related irritability.
The global autism spectrum disorder therapeutics market is poised for consistent growth, driven by factors such as rising prevalence, government initiatives, and ongoing research. The adoption of novel therapies, including enzyme replacement therapy, reflects the industry's dynamic nature. However, challenges in drug development and the lack of a cure for ASD core symptoms present obstacles. Continuous R&D efforts, strategic acquisitions, and increasing awareness contribute to a competitive landscape with key players dominating the market. The segmentation by drug therapy, disease, age group, and distribution channel provides insights into the market dynamics, while regional analysis highlights varied growth patterns globally. The market's future trajectory depends on overcoming current challenges and addressing the evolving needs of individuals with autism spectrum disorder.
In 2022, the global market for therapeutics addressing autism spectrum disorder (ASD) reached a valuation of USD 1.94 billion. The market is anticipated to demonstrate consistent growth, projected to increase from USD 2.05 billion in 2023 to USD 3.43 billion by 2030.
The global market is projected to grow at a CAGR of 7.90% during the forecast period, 2023-2032.
Research on the market is done by industry professionals who provide personalized insights on the industry structure, market segmentation, Type assessment, competitive landscape (CL), along with penetration, and emerging trends. In addition to years of professional experience in their various fields and sectors, their analysis is largely based on primary interview (60%) and secondary research (40%) as well as years of professional experience. In addition, our researchers forecast the market's direction over the following seven years by examining past trends and the market's current position. Additionally, various trends of segments and categories that are geographically portrayed are studied and estimated using primary and secondary research.
The key level executives (VP, CEO, Marketing Directors, and Business Development Managers) of the major industry participants who are active and prominent as well as mid-scale businesses operating in this market were interviewed in-depth for this supply-side report by overall Global Market Research.
Extensive primary research was conducted to gain a deeper grasp of the market and industry. Both primary and secondary research, as well as years of pertinent professional experience, are used to support the analysis. By analyzing past and present market patterns, our experts were able to forecast the market's course over the following seven years. For the geographically offered categories in the list of market tables, it differs per category. In connection with the Global Market research report, we also conducted a number of primary interviews with senior level executives (VP, CEO's, Directors, Marketing Directors, Business Development Managers, CFOs, Technical Consultants, Key Opinion Leaders, Industry Experts, Decision Matrix Authorities, and other crucial individuals) of the key industry players who dominated the Global market.
The primary purpose of secondary research was to gather, identify, and validate the information necessary for the thorough, technical, market-focused, and commercial analysis of the global market. With the use of this study, it was also possible to classify and segment the market in accordance with market trends, geographic markets, and regional considerations linked to market type. Analysts have gathered data in the Distribution Channel for the study of the market from reliable sources including annual reports, journals, white papers, corporate presentations, company websites, international organizations of Energy and Power manufacturers, credible paid databases, and many others to gather reliable intel.
Both top-down and bottom-up methodologies were employed to assess the accuracy of the global market size. The market for as a whole was estimated using these methods for a number of different dependent submarkets. Secondary research was used to address the major industry players, and primary and secondary research was used to calculate their market shares in the various regions. This complete intellectual process includes reading the annual and financial reports of the top market participants and conducting in-depth interviews with top industry executives (VP, CEO, Marketing Directors, and Business Development Managers) to gain important industry insights.
Through reliable secondary sources and validated primary sources, the classification of the global markets and their geographic percentage splits were established. To obtain the final qualitative and quantitative data, all relevant variables that might have an impact on the market under investigation have been taken into consideration, inspected in great depth, verified through primary research, and assessed. This information was collected, added to, and thoroughly examined by professional analysts before being provided in this report. The process used to estimate the overall market size for this study is depicted in the following image as an example.
Report Code :
RL65449
Published on :
Upcoming
Request a Free Sample Report
Speak to Analyst